120 related articles for article (PubMed ID: 23167337)
1. Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk.
Chen T; Yi SH; Liu XY; Liu ZG
Asian Pac J Cancer Prev; 2012; 13(9):4327-30. PubMed ID: 23167337
[TBL] [Abstract][Full Text] [Related]
2. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
[TBL] [Abstract][Full Text] [Related]
3. Association between murine double minute 2 T309G polymorphism and risk of liver cancer.
Tang T; Song X; Yang Z; Huang L; Wang W; Tan H
Tumour Biol; 2014 Nov; 35(11):11353-7. PubMed ID: 25119589
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of the MDM2 T309G polymorphism and gastric cancer risk.
Song B; Duan ZY; Zhong YH; Lei N; Yang YQ; Luo KY
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6649-51. PubMed ID: 24377582
[TBL] [Abstract][Full Text] [Related]
5. Role of MDM2 T309G polymorphism in susceptibility and prognosis of nonsmall cell lung cancer: a meta-analysis.
Kong Q; Li P; Tian Q; Ha MW
Genet Test Mol Biomarkers; 2014 May; 18(5):357-65. PubMed ID: 24673452
[TBL] [Abstract][Full Text] [Related]
6. Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis.
Yan YL; Han F; Tan WM; Wu CP; Qin X
Asian Pac J Cancer Prev; 2014; 15(16):6767-72. PubMed ID: 25169523
[TBL] [Abstract][Full Text] [Related]
7. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.
Zhuo W; Zhang L; Zhu B; Ling J; Chen Z
PLoS One; 2012; 7(7):e41546. PubMed ID: 22844496
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.
Zhuo W; Zhang L; Ling J; Zhu B; Chen Z
Leuk Lymphoma; 2012 Nov; 53(11):2245-52. PubMed ID: 22563815
[TBL] [Abstract][Full Text] [Related]
9. MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis.
Liu J; Zheng Y; Lei D; Liu D; Xu F; Jin T; Cao X; Zhao X; Yu X; Pan X
Asian Pac J Cancer Prev; 2011; 12(8):1899-903. PubMed ID: 22292622
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis.
Liu GY; Jiang DK; Shen SQ; Yu L
Arch Med Res; 2011 Feb; 42(2):149-55. PubMed ID: 21565629
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.
Xue Z; Zhu X; Teng Y
Med Sci Monit; 2016 Sep; 22():3186-90. PubMed ID: 27604213
[TBL] [Abstract][Full Text] [Related]
12. The T309G murine double minute 2 gene polymorphism is an independent prognostic factor for patients with renal cell carcinoma.
de Martino M; Taus C; Wessely IS; Lucca I; Hofbauer SL; Haitel A; Shariat SF; Klatte T
DNA Cell Biol; 2015 Feb; 34(2):107-12. PubMed ID: 25415135
[TBL] [Abstract][Full Text] [Related]
13. Association of
Sivonova MK; Jurecekova J; Kaplan P; Hives M; Grendar M; Tomascova A; Dusenka R; Drobkova H; Evin D; Kliment J
Anticancer Res; 2020 Nov; 40(11):6257-6264. PubMed ID: 33109563
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.
Zhao E; Cui D; Yuan L; Lu W
Mol Biol Rep; 2012 Apr; 39(4):3471-7. PubMed ID: 21725850
[TBL] [Abstract][Full Text] [Related]
15. Current evidence on the relationship between murine double minute 2 T309G polymorphism and esophageal cancer susceptibility.
Chen B; Xiong MM; Meng XL
Dis Esophagus; 2015; 28(6):593-601. PubMed ID: 24844868
[TBL] [Abstract][Full Text] [Related]
16. Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis.
Ma HB; Huang T; Han F; Chen WY
Asian Pac J Cancer Prev; 2012; 13(6):2841-6. PubMed ID: 22938470
[TBL] [Abstract][Full Text] [Related]
17. The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.
Ma YY; Guan TP; Yao HB; Yu S; Chen LG; Xia YJ; He XJ; Wang HJ; Jiang XT; Tao HQ
PLoS One; 2013; 8(1):e55019. PubMed ID: 23383041
[TBL] [Abstract][Full Text] [Related]
18. Association of MDM2 promoter T309G polymorphism with oral cancer risk: A meta-analysis of 3,536 subjects.
Yang XI; Zhu Y; Ye D; Liu Y; Sun H; Ruan M; Liu W
Mol Clin Oncol; 2016 Jul; 5(1):175-180. PubMed ID: 27330794
[TBL] [Abstract][Full Text] [Related]
19. MDM2 oncogene, E3 ubiquitin protein ligase T309G polymorphism and risk of oesophageal or gastric cancer: meta-analysis of 15 studies.
Shen W; Hu P; Cao JQ; Liu XX; Shao JH
J Int Med Res; 2014 Oct; 42(5):1065-76. PubMed ID: 25070969
[TBL] [Abstract][Full Text] [Related]
20. Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta-analysis.
Yin L; Shen G; Zhu B
Thorac Cancer; 2020 Mar; 11(3):672-678. PubMed ID: 31970867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
